A simpler process
to save you time.
[
]+ [
]=
Two test results.
Now from only one
patient blood draw!
Less hassle.
More convenience.
We are pleased to announce the next laboratory improvement to
provide you and your patient a new level of convenience. Now
you can perform one patient draw (2 tubes), request two tests,
and ship the sample to one location. We’ll do the rest, and report
the results back in about 5-7 days.
Greater office efficiency—pack and ship to one location
No need to store separate collection boxes
Spare your patients an additional blood draw
✓
®
®
✓
✓
✓
Start now!
Simply check the box for both MaterniT21® PLUS
and the HerediT™ CF carrier screening
laboratory-developed tests on the Test
Requisition Form, and we’ll provide both results
from the same patient blood draw.
Innovative solutions. Class-leading results.
One blood draw.
Two clinically relevant
test results.
Clearly revolutionary.
Clinically relevant.
A comprehensive, noninvasive prenatal test
(NIPT) that analyzes the relative amount of
chromosomal material for 21, 18, 13 and fetal
gender from a maternal blood draw.
An advanced CF carrier screening test with
a broad set of disease-causing mutations
confirmed in the CFTR2 project database.
No changes to billing. No changes to the
world-class customer service that you have
come to rely on.
Other chromosomal material, including
fetal chromosome 22, 16, sex chromosome
(X and Y) representation, and Enhanced
Sequencing Series that includes select
microdeletions are also evaluated, and will
only be reported as an Additional Finding
when an abnormality is detected.
Only mutations found to be phenotypically
relevant are reported.
This approach provides meaningful results
with less clinical uncertainty.
Sequenom®, MaterniT21® PLUS, and HerediT™ are trademarks of Sequenom, Inc. and are used with permission by Sequenom
Center for Molecular Medicine, LLC, dba Sequenom Laboratories. ©2014 Sequenom Laboratories. All rights reserved.
The MaterniT21® PLUS and the HerediT™ CF (Cystic Fibrosis Carrier Screen) tests are laboratory-developed tests that were
developed, validated and are performed exclusively by Sequenom Laboratories in the USA. They have not been cleared or
approved by the U.S. Food and Drug Administration (FDA). Although laboratory-developed tests to date have not been subject to
US FDA regulation, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. Sequenom
Laboratories is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity
clinical laboratory testing and accredited by the College of American Pathologists (CAP).
31-20255R1.1 0914
For further information, or to hear more about
what makes these tests special, contact
your local Sequenom Laboratories Business
Development Manager or contact Sequenom
Laboratories at 877.821.7266. Or simply email
us at [email protected].